We are glad to inform you that now your favourite Russian Peptide Semax® is now available in our store at affordable prices!
Now some information about this drug: What is it and what functions it has?
Semax peptide (0.1% solution) is a synthetic heptapeptide analogous to ACTH fragment 4-10 lacking hormonal activity. Semax belongs to the group of neuropeptides with nootropic and adaptive effects. Semax is a peptide with an original amino acid sequence. It appeared in the international press in 1982 and has been developed and tested for a decade and a half.
After administration by nasal drip, up to 70% is absorbed through the nasopharyngeal mucosa after a short period of time (1-5 minutes). One drop of 0.1 % Semax drops contain 50 µg of synthetic heptapeptide. A 3 ml bottle contains 0.1% Semax, 0.1% Nipagin (as a preservative) and distilled water.
Advantages:
- positively affects processes related to memory formation and learning;
- increases selective attention during learning and analysis of information;
- improves adaptation of the organism to hypoxia, cerebral ischaemia, anaesthesia;
- increases energy;
- promotes resistance to stress injuries and hypoxia
Indications
- Intellectual and mental disorders in vascular brain damage;
- Recovery period after a stroke;
- For the prevention of mental fatigue;
- At monotonous operator’s work;
- Work in stressful conditions;
- Optic atrophy;
- Optic neuritis.
You can buy Semax in our online shop at affordable prices. We also can deliver your order fast internationally.
- Cerebrolysin 10 x 2 ml- Cerebrolysin 5 x 5 ml- Cerebrolysin 5 x 10 ml Cerebrolysin is a neurometabolic stimulator based on neuropeptides (20 percent) and amino acids (80 percent) isolated from pig brain tissue.
It was developed in 1949 by Gerhart Harrer, an Austrian professor, and approved on August 1, 1954.
Used as a treatment for: - Strokes and complications associated with strokes- Depression, anxiety, and other brain diseases- Alzheimer's disease and other types of dementia- Traumatic brain injury and spinal cord injuries- ADHD in children Country of Manufacture: Austria Contraindications– individual intolerance to the drug– acute renal failure– status epilepticus Side effects– fever, sensation of heat (with rapid intravenous infusion)Rarely:– headache, dizziness– loss of appetite, nausea, vomiting, dyspepsia, diarrhea, constipation– allergic reactions: skin redness, itching and burning at the injection site Mode of applicationIt is used only parenterally: in the form of intramuscular injections (up to 5 ml), and intravenous infusions (10-60 ml), it is recommended to enter only by slow intravenous infusions after dilution with the proposed standard solutions for infusion.
Doses and duration of treatment depend on the nature and severity of the disease, as well as on the patient’s age.
The standard duration of treatment is 4 weeks (5 injections / infusions per week, preferably daily).To increase the effectiveness of treatment, repeated courses can be carried out until positive treatment results are obtained.
After the first course, the frequency of prescribing doses can be reduced to 2 or 3 times a week.In Alzheimer’s disease, dementia syndrome of various origins: intravenous infusion of 20-30 ml in 100-200 ml of saline, for a course of treatment 20 infusions, 5 infusions per week (followed by a 2-day break) for 28 days.
Neuropeptide Y Receptor Type 2 Market research report includes specific segments by region (country), by company, by Type and by Application.
This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027.
Understanding the segments helps in identifying the importance of different factors that aid the market growth.Download FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-neuropeptide-y-receptor-type-2021-499Segment by TypeXL-310NN-9748GT-002OthersSegment by ApplicationObesityEpilepsyType 2 DiabetesOthersBy RegionNorth AmericaU.S.CanadaEuropeGermanyFranceU.K.ItalyRussiaAsia-PacificChinaJapanSouth KoreaIndiaAustraliaTaiwanIndonesiaThailandMalaysiaPhilippinesVietnamLatin AmericaMexicoBrazilArgentinaMiddle East & AfricaTurkeySaudi ArabiaU.A.EBy CompanyGila Therapeutics IncNovo Nordisk A/SXL-protein GmbHGet the Complete Report & TOC @ https://www.grandresearchstore.com/life-sciences/global-neuropeptide-y-receptor-type-2021-499Table of content1 Neuropeptide Y Receptor Type 2 Market Overview1.1 Product Overview and Scope of Neuropeptide Y Receptor Type 21.2 Neuropeptide Y Receptor Type 2 Segment by Type1.2.1 Global Neuropeptide Y Receptor Type 2 Sales Growth Rate Comparison by Type (2021-2027)1.2.2 XL-3101.2.3 NN-97481.2.4 GT-0021.2.5 Others1.3 Neuropeptide Y Receptor Type 2 Segment by Application1.3.1 Neuropeptide Y Receptor Type 2 Sales Comparison by Application: (2021-2027)1.3.2 Obesity1.3.3 Epilepsy1.3.4 Type 2 Diabetes1.3.5 Others1.4 Global Neuropeptide Y Receptor Type 2 Market Size Estimates and Forecasts1.4.1 Global Neuropeptide Y Receptor Type 2 Revenue 2016-20271.4.2 Global Neuropeptide Y Receptor Type 2 Sales 2016-20271.4.3 Neuropeptide Y Receptor Type 2 Market Size by Region: 2016 Versus 2021 Versus 20272 Neuropeptide Y Receptor Type 2 Market Competition by Manufacturers2.1 Global Neuropeptide Y Receptor Type 2 Sales Market Share by Manufacturers (2016-2021)2.2 Global Neuropeptide Y Receptor Type 2 Revenue Market Share by Manufacturers (2016-2021)2.3 Global Neuropeptide Y Receptor Type 2 Average Price by Manufacturers (2016-2021)2.4 Manufacturers Neuropeptide Y Receptor Type 2 Manufacturing Sites, Area Served, Product Type2.5 Neuropeptide Y Receptor Type 2 Market Competitive Situation and Trends2.5.1 NeuropeptIf You Have Any Question Related To This Report Contact Us @ https://www.grandresearchstore.com/enquire-now/global-neuropeptide-y-receptor-type-2021-499CONTACT US:276 5th Avenue, New York, NY 10001, United StatesInternational: +1(646)-781-7170 / +91 8087042414Email: [email protected] Us On linkedin :- https://www.linkedin.com/company/grand-research-store
